Tue, Sep 2, 2014, 12:34 AM EDT - U.S. Markets open in 8 hrs 56 mins

Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

  • newsofal newsofal Jan 7, 2013 9:43 AM Flag

    SCLN to report in March

    •The Company anticipates 2013 sales revenue of $150 million - $155 million .
    •The Company expects 2013 non-GAAP EPS of $0.66 - $0.72 per share. SciClone's non-GAAP EPS excludes employee stock-based compensation from GAAP EPS.
    •The Company anticipates 2013 year-end cash and investments balances to be greater than $105 million excluding any impacts on cash balances associated with the Company's acquisition of new products, ongoing stock repurchase program and any other unbudgeted one-time cash expenses.
    •The Company expects cash and investments balances to be approximately $87 million (unaudited) at December 31, 2012 . Excluding the cash impact of fourth quarter 2012 repurchases of common stock from the Company's share repurchase program, cash and investments would have been approximately $93 million (unaudited). Excluding the cash impact of the full-year 2012 repurchases of common stock from the Company's share repurchase program, cash and investments would have been approximately $112 million (unaudited).

 
SCLN
6.86+0.23(+3.47%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exelixis, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Criteo SA
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT